The rising instances of hematologic malignancies and the inflating need to treat these conditions using radiotherapy and chemotherapy are primarily driving the minimal residual disease market.

1. Minimal Residual
Disease Market
Research Report
2023-2033

2. ABOUT IMARC
2
International Market Analysis Research and Consulting Group is a
leading adviser on management strategy and market research
worldwide. We partner with clients in all regions and industry
verticals to identify their highest-value opportunities, address their
most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific,
economic and technological developments for business leaders in
pharmaceutical, industrial, and high technology organizations.
Market forecasts and industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel and tourism,
nanotechnology and novel processing methods are at the top of
the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into
the dynamics of companies and markets with close cooperation at
all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient
organizations, and secure lasting results.

3. Report Description and Highlights
Minimal Residual Disease Market 2023-2033
IMARC Group has recently released a report titled “Minimal Residual Disease Market: Analysis of Epidemiology, Industry Trends, Size, Share, and
Future Forecast (2023-2033)” that presents a comprehensive assessment of the minimal residual disease market size. The report provides an
extensive overview of the latest market trends, growth prospects, investment opportunities, and industry outlook, as well as an in-depth
analysis of the disease landscape, market size, and growth trends. Furthermore, the report offers an analysis of competitors, regional markets,
and recent advancements in the global market. It also sheds light on crucial segments and market drivers, along with challenges faced by
industry players. This report is a valuable resource for stakeholders who want to gain valuable insights into the minimal residual disease
market.
Minimal residual disease (MRD) refers to a sub-microscopic disorder denoting the presence of a small number of cancer cells that survive in
the body following the initial treatment. These residual cells in the body can become reactive and proliferate, ultimately posing the risk of a
relapse occurring in the patient. There are generally no specific symptoms linked to MRD due to the small number of unhealthy cells. The
diagnosis of this condition is quite challenging using conventionally employed cytogenetic and morphologic assessments. However, MDR can
be detected through sensitive methods, such as multi-parametric flow cytometry and real-time quantitative polymerase chain reaction (PCR)
assays, CT scans, and PET scans. 3

4. Report Description and Highlights
Minimal Residual Disease Market Trend:
The rising instances of hematologic malignancies and the inflating need to treat these conditions using radiotherapy and chemotherapy are
primarily driving the minimal residual disease market. Additionally, the expanding geriatric population, who are more susceptible to chronic
health conditions owing to a weakened immune system, is also augmenting the market growth. Besides this, the escalating utilization of
intensive antineoplastic agents, such as blinatumomab, imatinib, dasatinib, etc., to destroy the residual tumor cells and improve overall
survival is creating a positive outlook for the market.
Moreover, various leading market players are increasingly investing in R&D activities to launch effective diagnostic tools with increased
sensitivity that can identify variations and other gene abnormalities, which in turn is acting as another significant growth-inducing factor.
Additionally, the rising popularity of targeted therapies, since they can be engineered and designed to inhibit specific molecules that are
essential for cancer cell growth and survival, is anticipated to propel the minimal residual disease market in the coming years.
Request a Sample Report: https://www.imarcgroup.com/minimal-residual-disease-market/requestsample
4

5. Report Description and Highlights
What is included in the report segmentation?
The report covers the following aspects:
Report Period:
• Base Year: 2022
• Historical Period: 2017-2022
• Market Forecast: 2023-2033
Countries Included:
• United States
• Germany
• France
5

6. Report Description and Highlights
• United Kingdom
• Italy
• Spain
• Japan
Analysis Covered Across Each Country
• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Minimal Residual Disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Minimal Residual Disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs
6

7. Report Description and Highlights
In-Market Drugs
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Regulatory Status
View Report TOC, Figures and Tables: https://www.imarcgroup.com/minimal-residual-disease-market
7

8. Key Questions Answered in the Report
1. How has the Minimal Residual Disease Market performed so far and how will it perform in the coming years?
2. What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
3. What was the country-wise size of the Minimal Residual Disease Market across the seven major markets in 2022 and what will it look
like in 2033?
4. What is the growth rate of the Minimal Residual Disease Market across the seven major markets and what will be the expected growth
over the next ten years?
5. What are the key unmet needs in the market?
8

9. Table of
Contents

10. Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
10

11. Table of Contents
4 Minimal Residual Disease - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2017-2022) and Forecast (2023-2033)
4.4 Market Overview (2017-2022) and Forecast (2023-2033)
4.5 Competitive Intelligence
5 Minimal Residual Disease - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
Click here to visit the complete table of content with list of figures and tables: https://www.imarcgroup.com/minimal-residual-disease-
market/toc
11

12. Partial List Of Our Clients
12

13. OUR CLIENTS
13

14. Disclaimer
14
© 2023 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis
Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or
in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including
photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information
and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting
makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts
no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and
Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.